Are We Overtreating DCIS?

Slideshow

With evidence from a number of studies, this presentation delves into the controversy surrounding the treatment, or overtreatment, of ductal carcinoma in situ (DCIS), and discusses whether or not these lesions should indeed be classified as breast cancer.

slideshow image

Are We Overtreating DCIS?

Recent Videos
Optimal Sequencing Strategies for CAR T and Bispecifics in R/R MM
Optimal Sequencing Strategies for CAR T and Bispecifics in R/R MM
PERSEUS Trial: MRD Negativity
PERSEUS Trial: MRD Negativity
PERSEUS Trial: Design/Baseline Characteristics
PERSEUS Trial: Design/Baseline Characteristics
Role of Talquetamab as Bridging Therapy for CAR T-Cell Therapy
Role of Talquetamab as Bridging Therapy for CAR T-Cell Therapy
The CHALLENGE Trial Helps Redefine Adjuvant Therapy with Exercise in CRC
The CHALLENGE Trial Helps Redefine Adjuvant Therapy with Exercise in CRC
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
Advances in NSCLC Bring Excitement in the Lung Space
5 experts are featured in this series
Expert Opinion on Modern Availability of Several Agents
2 experts are featured in this series.
CARTITUDE-1 Baseline Demographics
5 experts are featured in this series
Data Review of Teclistamab and Elranatamab in R/R MM
2 experts are featured in this series.
An Overview of CARTITUDE-1
Related Content
The Oncomine Dx Express Test may generate results in as little as 24 hours when used on the Ion Torrent Genexus Dx Integrated Sequencer.

FDA OKs NGS Test for Tumor Profiling, as CDx for Sunvozertinib in NSCLC

Roman Fabbricatore
July 7th 2025
Article

The Oncomine Dx Express Test may generate results in as little as 24 hours when used on the Ion Torrent Genexus Dx Integrated Sequencer.

Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board exams.

SIR-Sphere Y-90 resin microspheres are the only approved radioembolization treatments in the US for both HCC and mCRC.

FDA Approves SIR-Sphere Y-90 in HCC

Ariana Pelosci
July 7th 2025
Article

SIR-Sphere Y-90 resin microspheres are the only approved radioembolization treatments in the US for both HCC and mCRC.

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

No tracer-related adverse effects were observed in the study, with [18F]AIF-NOTA-PCP2 showing acceptable dosimetry in patients with head and neck cancers.

[18F]AIF-NOTA-PCP2 Shows PD-L1 Monitoring Potential in Head and Neck Cancer

Roman Fabbricatore
July 6th 2025
Article

No tracer-related adverse effects were observed in the study, with [18F]AIF-NOTA-PCP2 showing acceptable dosimetry in patients with head and neck cancers.

Confirmatory data may support zanidatamab as an advancement in the treatment of HER2-positive advanced gastroesophageal adenocarcinoma.

Zanidatamab Combo Has Meaningful Activity in HER2+ Gastroesophageal Cancer

Russ Conroy
July 5th 2025
Article

Confirmatory data may support zanidatamab as an advancement in the treatment of HER2-positive advanced gastroesophageal adenocarcinoma.